glp 1 agonist and blindness Eye doctors warn GLP-1 drugs for diabetes weight loss may pose rare vision risks, recommending regular checkups Mapping the effectiveness and risks

GLP-1RA medications are the first pharmacotherapy for obesity with demonstrable cardiovascular benefits and ASCVD risk reduction

Multiple studies highlight its potential applications in prevention

Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from gut enteroendocrine cells that modulates glucose metabolism by controlling insulin excretion and glucagon secretion and inhibits gastric emptying leading to decreased food intake, thus limiting weight gain

The hidden costs of silencing hunger with GLP-1s like Wegovy and Ozempic.

Glycemic monitoring with CGMs, glucose-lowering agents (GLP-1 receptor agonists), innovative insulin delivery systems, and mental health check-ins are just a few updates to the ADA 2025 Standards of Care.

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases